Conor Medsystems , Inc.

Industry:	Medical Devices & Equipment
Ranking:	Russell 3000
Revenues:	$23.2 Million
Employees:	180

Description

Conor Medsystems, LLC, founded in 1999, is a developer of innovative controlled vascular drug delivery technologies. Conor has initially focused on the development of drug-eluting stents to treat coronary artery disease. Conor is seeking to capitalize on the full therapeutic potential of drug-eluting stents through the development of a stent specifically designed for drug delivery. Rather than retrofitting a bare metal stent with a drug coating, Conor's stent design incorporates hundreds of small holes, each acting as a reservoir into which drug-polymer compositions can be loaded. Through this proprietary design, Conor believes that it can greatly enhance control of the rate and direction of drug delivery, enable a wider range of drug therapies and potentially increase the effectiveness and range of clinical applications of drug-eluting stents.

Conor's objective is to become a technological, clinical, and market leader in the field of controlled vascular drug delivery with innovative drug delivery stents. Conor's efforts are currently focused on the development of drug-eluting stents for the treatment of restenosis. Conor is also investigating the potential applicability of its stent technology for myocardial rescue in setting of acute MI, treatment of vulnerable plaque, treatment of reperfusion injury, and treatment of diabetic and metabolic syndrome restenosis.

Through a merger completed on February 1, 2007, Conor Medsystems, LLC became a wholly owned subsidiary of Johnson & Johnson, the world's most comprehensive and broadly based manufacturer of healthcare products.

Products & Services

controlled vascular drug delivery, drug-eluting stents, cardiovascular device, medical-device

View More Statistics

Site Statistics

Monthly Unique Visitors:	71
Site Rank:	4,251,130
Trust Rating:	Neutral
Stats by

News Archive

Nile Therapeutics Appoints Frank Litvack, M.D., to Board of Directors. PR Newswire; 9/25/2009 ...companies including Progressive Angioplasty Systems, Savacor, and most recently the $1.4 billion acquisition of Conor Medsystems by Johnson & Johnson. Dr. Litvack is board certified in internal medicine, cardiovascular diseases and interventional... ...more

Novartis: - A Detailed And Comprehensive Overview Of Current Financial Position, Company Strategy, Product And Pipeline Analysis. M2 Presswire; 12/3/2009 ...Celgene Corporation - Cell Genesys Inc - Cell Therapeutics Inc - Cerimon Pharmaceuticals Inc - Clinical Data Inc - Conor Medsystems Inc - Cytos Biotechnology AG - Cytopia Ltd - Dynavax Technologies Corp - Elan Corporation plc - Emisphere Technologies... ...more

Highland Capital Partners Announces $400 Million Fund. Investment Weekly News; 11/28/2009 ...with valuations in excess of $1 billion include Conor Medsystems (IPO/acquired by Johnson & Johnson), lululemon...firms as Ask Jeeves, Avid Technology, CheckFree, Conor Medsystems, Continental Cable, lululemon athletica, Lycos... ...more